Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.49 |
| ▸ | MMP8 | P22894 | 8/20 | 0.45 |
| ▸ | MMP13 | P45452 | 8/20 | 0.45 |
| ▸ | MMP2 | P08253 | 7/20 | 0.45 |
| ▸ | MMP3 | P08254 | 7/20 | 0.45 |
| ▸ | MMP9 | P14780 | 7/20 | 0.45 |
| ▸ | MMP1 | P03956 | 6/20 | 0.45 |
| ▸ | MMP7 | P09237 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3986279 | 0.91 | GPR119 (0.51) | GPR119 | |
| SCHEMBL3979941 | 0.90 | GPR119 (0.47) | GPR119MMP8MMP13 | |
| SCHEMBL3982861 | 0.88 | GPR119 (0.53) | GPR119 | |
| SCHEMBL3982839 | 0.88 | GPR119 (0.58) | GPR119 | |
| SCHEMBL3982586 | 0.87 | GPR119 (0.50) | GPR119MMP8MMP2MMP3MMP9 | |
| SCHEMBL3980367 | 0.87 | GPR119 (0.53) | GPR119 | |
| SCHEMBL3980525 | 0.87 | GPR119 (0.48) | GPR119 | |
| SCHEMBL12569747 | 0.86 | GPR119 (0.66) | GPR119 | |
| SCHEMBL3979923 | 0.86 | GPR119 (0.56) | GPR119 | |
| SCHEMBL3982636 | 0.85 | GPR119 (0.48) | GPR119MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | claimed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | claimed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | claimed |
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | GPR119 1/4885MMP8 4108/4885MMP13 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.